Christina Yap

ORCID: 0000-0002-6715-2514

Colleges, School and Institutes

Willingness to take PhD students

Yes

View graph of relations

Most downloaded publications

A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma
Christina Yap, Ceri Oldreive, Daniel Slade, Paul Moss & Tatjana Stankovic, Aug 2018, In : British Journal of Haematology. 182, 3, p. 429-433

Research output: Contribution to journal › Letter

198 downloads
How to design a dose-finding study using the continual reassessment method
Kristian Brock, Christina Yap, 18 Jan 2019, In : BMC Medical Research Methodology. 19, 1, 15 p., 18.

Research output: Contribution to journal › Article

196 downloads
Embracing model-based designs for dose-finding trials
Christina Yap & Charles Craddock, 25 Jul 2017, In : British Journal of Cancer. 117, 3, p. 332-339 8 p.

Research output: Contribution to journal › Article

192 downloads
Adaptive designs in clinical trials: why use them, and how to run and report them
Christina Yap, 28 Feb 2018, In : BMC medicine. 16, 1, 29.

Research output: Contribution to journal › Article

189 downloads
Combination Lenalidomide and Azacitidine: A Novel Salvage Therapy in Patients Who Relapse After Allogeneic Stem-Cell Transplantation for Acute Myeloid Leukemia
Charles Craddock, Daniel Slade, Carmela De Santo, Rachel Hoare, Kristian Brock, Francis Mussai & Christina Yap, 1 Mar 2019, In : Journal of Clinical Oncology . 37, 7, p. 580-588 9 p., JCO1800889.

Research output: Contribution to journal › Article

160 downloads

Recent publications

Transplantation of discarded livers following viability testing with normothermic machine perfusion
Richard Laing, Amanda Kirkham, Stuart Curbishley, Desley Neil, Stefan Hubscher, Julian Bion, David Adams & 5 others, , Christina Yap, Simon Afford, 16 Jun 2020, In : Nature Communications. 11, 1, 2939.

Research output: Contribution to journal › Article

Phase I trial of WEE1 inhibition with chemotherapy and radiotherapy as adjuvant treatment, and a window of opportunity trial with cisplatin in patients with head and neck cancer: the WISTERIA trial protocol
Anthony Kong, Amanda Kirkham, Jo Parish, Rachel Spruce, Gary Middleton, Christina Yap & Hisham Mehanna, 16 Mar 2020, In : BMJ open. 10, 3, e033009.

Research output: Contribution to journal › Article

A Phase II Clinical Trial with Efficacy and Toxicity Outcomes and Baseline Covariates
Kristian Brock, Lucinda Billingham, Christina Yap & Gary Middleton, 27 Nov 2019, Bayesian Statistics: New Challenges and New Generations. Springer, p. 125-133 (Springer Proceedings in Mathematics & Statistics; vol. 296).

Research output: Chapter in Book/Report/Conference proceeding › Conference contribution

View all (39)

Recent Activities

A Phase II Clinical Trial with Efficacy and Toxicity Outcomes and Baseline Covariates

Kristian Brock (Speaker), , Lucinda Billingham (Contributor), , Gary Middleton (Contributor), & Christina Yap (Contributor)

2 Jul 2018

Activity: Talk or presentation › Academic conference

Implementing more novel designs in cancer clinical trials: the Birmingham experience

Lucinda Billingham (Presenter), , Christina Yap (Presenter), , Kristian Brock (Presenter), & Daniel Slade (Presenter)

26 Mar 2018

Activity: Talk or presentation › Invited talk

Assessing the design of our trial in an ultra-rare condition by the Parmar et al framework for trials in smaller populations

Kristian Brock (Speaker), , Lucinda Billingham (Contributor), , Christina Yap (Contributor), & Timothy Barrett (Contributor)

10 Jul 2017

Activity: Talk or presentation › Academic conference

View all (4)